Published in:
01-06-2017 | Editorial
Have biomarkers failed in acute kidney injury? We are not sure
Authors:
John R. Prowle, Mitchell H. Rosner
Published in:
Intensive Care Medicine
|
Issue 6/2017
Login to get access
Excerpt
Over the past decade, there has been an explosion of interest in the study of urinary and plasma biomarkers for the rapid diagnosis, molecular phenotyping and prognostication of acute kidney injury (AKI) with over 3300 publications devoted to this topic listed in PubMed during the past 10 years. More than 15 separate biomarkers, plasma and urine, have been identified and investigated to various levels, the majority in the context of AKI complicating critical illness [
1]. However, opinion remains divided as to the
clinical value of biomarker measurements in the care of patients at risk or with AKI, as reflected in opposing opinion pieces in this issue of
Intensive Care Medicine. While we agree that AKI biomarkers are not ready for implementation in routine care, we feel that progress is being made and that, ultimately, there may be important roles for these tools in the care of critically ill patients. …